Inclusion of pathogenic mechanisms in treatment design will allow ... and its more severe form NASH are common liver diseases in industrialized countries. Diabetes, obesity, the metabolic syndrome ...

No treatments currently exist for the fatty ... The condition represents a silent epidemic: a major cause of liver disease worldwide, NASH is now the number one cause of liver transplants for ...

Liver disease affects millions of adults in the United States, posing serious risks to health if left untreated. Among the ...

Metabolic dysfunction-associated steatohepatitis (MASH) is a disease in which a buildup of fat causes inflammation and damage to the liver. It used to be called nonalcoholic steatohepatitis (NASH).

The liver serves as a crucial command center for numerous bodily functions, including detoxification, metabolism, and ...

Cirrhosis is the severe scarring or fibrosis of the liver. It happens in the late stage of liver disease and other conditions that involve liver damage. The scarring that occurs with cirrhosis is ...

Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the top-line results of the NAVIGATE trial in patients with MASH cirrhosis and portal ...

Biomarker staging of liver fibrosis in hepatitis C was cost effective, but so was initiating treatment without testing.

In a matter of a few months, he went from a NASH diagnosis ... including the treatment of conditions like MASLD. Given the clear connection between obesity and liver disease, it’s critical ...